Chinese health authorities could change their vaccine strategy taking into account the latest studies suggesting greater efficacy of vaccines than ARN messenger. While, for now, the country only allows products developed on its soil, the BioNTech vaccine should soon make its appearance.
Is China going to change its tune regarding the Covid-19 vaccination? So far, the country has only authorized vaccines developed on its territory: the CoronaVac from the private laboratory Sinovac, the WIBP-CorV and BBIBP-CorV vaccines from the public laboratory Sinopharm, and finally the Convidecia from the company CanSino Biologics .
However, China could well turn to foreign vaccines, in particular the Fubitai (Pfizer / BioNTech), understands the economic magazine Caixin. On July 14, the magazine revealed that Chinese authorities are considering using the vaccine as a booster for people who have received inactivated virus vaccines.
More antibodies in “Pfizer vaccinees”
Coincidence of the calendar or not, the next day a study was published in the prestigious scientific journal The Lancet, that tarnishes the CoronaVac vaccine crest. “Research has found that antibody levels in Hong Kong health workers who have been fully vaccinated with BioNTech SE mRNA injection, are approximately ten times higher than those observed in recipients of the inactivated vaccine from Sinovac Biotech Ltd”, Reported the agency Bloomberg the day after publication.
For its research, the team from the Li Ka Shing Faculty of Medicine at the University of Hong Kong – also the World Health Organization (WHO) collaborating center for the epidemiology and control of infectious diseases – has analyzed blood samples from 93 people before vaccination, after the first dose, and then between 21 and 35 days after the second. 63 participants received the Pfizer, the others the Sinovac. The level of neutralizing antibodies, proteins that neutralize the effects
Agnès Gaudu and Nina Schretr